Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559032 | 1.00 | ALDH1A1 (0.53) | ALDH1A1P2RX7TSHRNPSR1GAA | |
| SCHEMBL8370379 | 0.83 | ALDH1A1 (0.42) | ALDH1A1P2RX7TSHRNPSR1GAA | |
| SCHEMBL21012913 | 0.81 | ALDH1A1 (0.41) | ALDH1A1P2RX7TSHRNPSR1GAA | |
| SCHEMBL15431053 | 0.81 | SIGMAR1 (0.56) | ALDH1A1TSHRNPSR1 | |
| SCHEMBL3840366 | 0.81 | P2RX7 (0.49) | P2RX7TSHRPIN1HDAC4HDAC7 | |
| SCHEMBL31300387 | 0.81 | P2RX7 (0.45) | ALDH1A1P2RX7GAAPIN1HDAC4 | |
| SCHEMBL3649959 | 0.81 | P2RX7 (0.45) | ALDH1A1P2RX7GAAPIN1HDAC4 | |
| SCHEMBL13979540 | 0.81 | P2RX7 (0.45) | P2RX7PIN1HDAC4HDAC7HDAC5 | |
| SCHEMBL4036815 | 0.80 | MAOA (0.48) | ALDH1A1TSHRNPSR1HDAC4HDAC7 | |
| SCHEMBL5731810 | 0.80 | MAOA (0.48) | ALDH1A1TSHRNPSR1HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-26 | — | — | US | claimed |
| EP-1951685-A1 | NOVEL QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-08-06 | — | — | EP | claimed |
| WO-2007057447-A1 | NOVEL QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-05-24 | — | — | WO | claimed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| US-6398857-B1 | ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS | XEROX CORPORATION | 2002-06-04 | — | — | US | claimed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | claimed |
| US-4954584-A | Thermosetting resin compositions | SHELL OIL COMPANY (US) | 1990-09-04 | — | — | US | claimed |
| JP-3081253-A | — | — | None | — | — | JP | disclosed |
| EP-4563146-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-06-04 | — | — | EP | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-5068396-A | Arylcyclobutene carboxylate esters | SHELL OIL COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| JP-H0381253-A | BENZOCYCLOBUTENECARBOXYLIC ACID ESTER | SHELL INTERNATL RES MAATSCHAPPIJ BV | 1991-04-05 | — | — | JP | disclosed |
| EP-0402975-A2 | Benzocyclobutene carboxylate esters | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-12-19 | — | — | EP | disclosed |
| US-4954583-A | Arylcyclobutene carboxylate esters | SHELL OIL COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| US-4954584-A | Thermosetting resin compositions | SHELL OIL COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0043194-A2 | Bicyclo-octatriene derivatives, pharmaceutical compositions containing them and processes and intermediates for their production | FISONS plc (GB) | 1982-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | ALDH1A1 3140/4885P2RX7 3834/4885TSHR 1793/4885 |
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | KCNA7, KCNN3, KCNQ5 | ALDH1A1 3467/4885P2RX7 57/4885TSHR 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.